255641001: Caffeine (substance)

SNOMED CT Concept\Substance\...

\Substance categorized by disposition\Substance with effector mechanism of action (substance)\Enzyme inhibitor\Hydrolase inhibitor\Phosphodiesterase inhibitor\Caffeine

\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Respiratory system agent (substance)\Methyl xanthine\Caffeine
\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Central nervous system agent (substance)\Psychoactive substance (substance)\Psychotropic agent (substance)\Psychostimulant (substance)\Caffeine
\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Central nervous system agent (substance)\Stimulant (substance)\Psychostimulant (substance)\Caffeine

\Substance categorised by structure\Chemical\Chemical categorized by structure (substance)\...

\Nitrogen and/or nitrogen compound (substance)\Nitrogen compound\Organic nitrogen compound\Purine and/or purine derivative\Xanthine and/or xanthine derivative (substance)\Xanthine derivative (substance)\Methyl xanthine\Caffeine

\Substance categorized functionally\Phytochemical\Caffeine

\Material (substance)\Natural material\Organic natural material\Plant material\Phytochemical\Caffeine

\Biological substance (substance)\Organic natural material\Plant material\Phytochemical\Caffeine

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2002. Module: SNOMED CT core

Descriptions:

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
Caffeine	Is a	Phytochemical	true	Inferred relationship	Some
Caffeine	Is a	Xanthine	false	Inferred relationship	Some
Caffeine	Is a	Central nervous system agent (substance)	false	Inferred relationship	Some
Caffeine	Is a	Drug allergen	false	Inferred relationship	Some
Caffeine	Is a	Methyl xanthine	true	Inferred relationship	Some
Caffeine	Is a	centralrespiratorisk stimulans	false	Inferred relationship	Some
Caffeine	Is a	Phosphodiesterase inhibitor	true	Inferred relationship	Some
Caffeine	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Phosphodiesterase inhibitor (disposition)	true	Inferred relationship	Some
Caffeine	Is a	Enzyme inhibitor	false	Inferred relationship	Some
Caffeine	Is a	Psychostimulant (substance)	true	Inferred relationship	Some

Inbound Relationships	Type	Active	Source	Characteristic	Refinability	Group
koffein og natriumbenzoat injektionsvæske, opløsning, hætteglas	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Accidental caffeine poisoning	Causative agent	False	Caffeine	Inferred relationship	Some
Intentional caffeine poisoning	Causative agent	False	Caffeine	Inferred relationship	Some
forgiftning med koffein, uvist med hvilken hensigt	Causative agent	False	Caffeine	Inferred relationship	Some	1
Caffeine overdose	Causative agent	True	Caffeine	Inferred relationship	Some	1
Accidental caffeine overdose	Causative agent	True	Caffeine	Inferred relationship	Some	1
Intentional caffeine overdose	Causative agent	True	Caffeine	Inferred relationship	Some	1
overdosis af koffein, uvist med hvilken hensigt	Causative agent	False	Caffeine	Inferred relationship	Some	1
Caffeine-related disorder (disorder)	Causative agent	True	Caffeine	Inferred relationship	Some	1
Organic mental disorder caused by caffeine (disorder)	Causative agent	True	Caffeine	Inferred relationship	Some	1
Plasma caffeine measurement	Component	False	Caffeine	Inferred relationship	Some	2
Serum caffeine measurement	Component	False	Caffeine	Inferred relationship	Some	2
Caffeine solution	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
caffein 5 mg/ml injektionsvæske, opløsning, hætteglas a 2 ml	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
caffeincitrat 20 mg/ml injektionsvæske, opløsning, ampul	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Caffeine citrate 20mg solution	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Caffeine + ergotamine tartrate 100mg/1mg tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Caffeine + ergotamine tartrate 100mg/2mg suppository (product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Caffeine measurement	Component	True	Caffeine	Inferred relationship	Some	1
acetylsalicylsyre + caffein + orphenadrincitrat tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing caffeine in oral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Caffeine-containing product in rectal dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing caffeine in parenteral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Sleep disorder caused by caffeine (disorder)	Causative agent	True	Caffeine	Inferred relationship	Some	1
Poisoning by caffeine	Causative agent	True	Caffeine	Inferred relationship	Some	1
Caffeine-induced anxiety disorder	Causative agent	False	Caffeine	Inferred relationship	Some	2
koffeinintoksikation	Causative agent	False	Caffeine	Inferred relationship	Some
Product containing caffeine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Caffeine withdrawal	Causative agent	False	Caffeine	Inferred relationship	Some	1
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
acetylsalicylsyre + butalbital + caffein + codeinphosphat	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
paracetamol + caffein + isometheptenmucat	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
acetylsalicylsyre + caffein + propoxyphenhydrochlorid	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
acetylsalicylsyre + caffein + dihydrocodeinbitartrat	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Caffeine + ergotamine tartrate	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing caffeine and sodium benzoate (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	2
Product containing butalbital and caffeine and paracetamol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
acetylsalicylsyre + caffein + orphenadrincitrat	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
paracetamol + butalbital + caffein + codeinphosphat	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing aspirin and butalbital and caffeine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Caffeine 100 mg and ergotamine tartrate 2 mg rectal suppository	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
paracetamol + caffein + dihydrocodeinbitartrat	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing aspirin and caffeine and cinnamedrine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing aspirin and caffeine and orphenadrine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing caffeine and paracetamol and salicylamide (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	2
Product containing buffered aspirin and caffeine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing aspirin and caffeine and paracetamol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing aspirin and caffeine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
ergotamin + caffein	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Caffeine citrate (substance)	Is a	False	Caffeine	Inferred relationship	Some
Intentional caffeine poisoning	Causative agent	True	Caffeine	Inferred relationship	Some	1
[X]Adverse reaction to caffeine	Causative agent	False	Caffeine	Inferred relationship	Some
Product containing precisely caffeine 65 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing precisely caffeine 30 milligram and paracetamol 450 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Caffeine 25 mg and paracetamol 450 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Product containing caffeine and paracetamol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
paracetamol 500 mg + caffein 65 mg opløselig tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Accidental poisoning by caffeine	Causative agent	True	Caffeine	Inferred relationship	Some	1
Adverse reaction to caffeine	Causative agent	True	Caffeine	Inferred relationship	Some	1
Allergy to caffeine	Causative agent	False	Caffeine	Inferred relationship	Some
Product containing caffeine and ergotamine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing ammonium chloride and caffeine (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
Product containing caffeine and glucose (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Caffeine	Inferred relationship	Some	1
fioricet med codein 325 mg/50 mg/40 mg/30 mg, kapsel	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some
Caffeine dependence (disorder)	Causative agent	True	Caffeine	Inferred relationship	Some	1
Allergy to caffeine	Causative agent	True	Caffeine	Inferred relationship	Some	1
A pattern of caffeine use that has caused clinically significant harm to a person's physical or mental health or in which caffeine-induced behaviour has caused clinically significant harm to the health of other people. The pattern of caffeine use is evident over a period of at least 12 months if use is episodic and at least one month if use is continuous (daily or almost daily). Harm may be caused by the intoxicating effects of caffeine, the direct or secondary toxic effects on body organs and systems, or a harmful route of administration.	Causative agent	True	Caffeine	Inferred relationship	Some	1
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	4
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	4
Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	3
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	2
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	2
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Caffeine 25 mg and paracetamol 450 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	3
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	3
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Caffeine	Inferred relationship	Some	2
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Caffeine	Inferred relationship	Some	2
Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Caffeine	Inferred relationship	Some	1

Page 1 of 4 Next End

This concept is not in any reference sets

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
380891010	Caffeine	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
646709011	Caffeine (substance)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
3899921000005118	coffein	da	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	Danish module (core metadata concept)
4842501000005116	caffein	da	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	Danish module (core metadata concept)